Atrial Fibrillation Ablation in Octogenarians: Where Do We Stand?

被引:0
|
作者
Gevorg Stepanyan
Edward P. Gerstenfeld
机构
[1] University of California,
[2] San Francisco,undefined
来源
关键词
Atrial fibrillation; Ablation; Elderly; Octogenarians; Stroke; Anticoagulation;
D O I
暂无
中图分类号
学科分类号
摘要
The prevalence of atrial fibrillation increases significantly with age, affecting nearly 10 % of adults greater than 80 years of age. Complications from atrial fibrillation, including stroke, also increase with age. Medical therapy includes anticoagulation, ventricular rate control, and if symptoms persist, maintenance of sinus rhythm with antiarrhythmic drugs. However, anticoagulation and antiarrhythmic therapy is often challenging in the elderly due to side effects, comorbidities, and heightened sensitivity to medications. Catheter based ablation of atrial fibrillation is an effective treatment for paroxysmal atrial fibrillation. However, the major randomized controlled trials, such as Thermocool AF and STOP-AF studies, have excluded the elderly patients. Current guidelines suggest caution when considering ablation for elderly patients due to a lack of available data. We will review recent studies that have observed the outcomes of atrial fibrillation ablation in the elderly, specifically those studies that included octogenarians.
引用
收藏
相关论文
共 50 条
  • [41] Catheter Ablation of Atrial Fibrillation in Octogenarians: Safety and Outcomes
    Santangeli, Pasquale
    Di Biase, Luigi
    Mohanty, Prasant
    Burkhardt, J. David
    Horton, Rodney
    Bai, Rong
    Mohanty, Sanghamitra
    Pump, Agnes
    Gibson, Douglas
    Couts, Linda
    Hongo, Richard
    Beheiry, Salwa
    Natale, Andrea
    [J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2012, 23 (07) : 687 - 693
  • [42] Concomitant ablation of atrial fibrillation in octogenarians: an observational study
    Grubitzsch, Herko
    Beholz, Sven
    Dohmen, Pascal M.
    Dushe, Simon
    Konertz, Wolfgang
    [J]. JOURNAL OF CARDIOTHORACIC SURGERY, 2008, 3 (1)
  • [43] Point-of-care screening for atrial fibrillation: Where are we, and where do we go next?
    Ashburner, Jeffrey M.
    Khurshid, Shaan
    Atlas, Steven J.
    Singer, Daniel E.
    Lubitz, Steven A.
    [J]. CARDIOVASCULAR DIGITAL HEALTH JOURNAL, 2021, 2 (06): : 294 - 297
  • [44] Epilepsy: Where do we stand? Where are we headed?
    Elger, C. E.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 8 - 8
  • [45] ColVI myopathies: where do we stand, where do we go?
    Valérie Allamand
    Laura Briñas
    Pascale Richard
    Tanya Stojkovic
    Susana Quijano-Roy
    Gisèle Bonne
    [J]. Skeletal Muscle, 1
  • [46] Rye and health - Where do we stand and where do we go?
    Jonsson, Karin
    Andersson, Roger
    Knudsen, Knud Erik Bach
    Hallmans, Goran
    Hanhineva, Kati
    Katina, Kati
    Kolehmainen, Marjukka
    Kyro, Cecilie
    Langton, Maud
    Nordlund, Emilia
    Laerke, Helle Nygaard
    Olsen, Anja
    Poutanen, Kajsa
    Tjonneland, Anne
    Landberg, Rikard
    [J]. TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2018, 79 : 78 - 87
  • [47] Investigative dermatology: where do we stand and where do we go?
    Maurer, M.
    von Stebut, E.
    [J]. EXPERIMENTAL DERMATOLOGY, 2010, 19 (10) : 857 - 857
  • [48] ColVI myopathies: where do we stand, where do we go?
    Allamand, Valerie
    Brinas, Laura
    Richard, Pascale
    Stojkovic, Tanya
    Quijano-Roy, Susana
    Bonne, Gisele
    [J]. SKELETAL MUSCLE, 2011, 1
  • [49] Do we need pharmacological therapy for atrial fibrillation in the ablation era?
    Levy, Samuel
    [J]. JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2006, 17 (03) : 189 - 194
  • [50] Do we need pharmacological therapy for atrial fibrillation in the ablation era?
    Samuel Lévy
    [J]. Journal of Interventional Cardiac Electrophysiology, 2006, 17 : 189 - 194